One of the most hopeful numbers in American public health right now is the drop in overdose deaths, down about 13 percent in the most recent CDC provisional data, among the steepest declines on record. The decline is real. The explanation attached to it, that a border and tariff crackdown on fentanyl is driving it, does not match what the drug-supply data and the government's own seizure numbers show.
Researchers who study the supply point elsewhere. The leading explanations are a weaker fentanyl supply, linked to Chinese controls on the export of the chemical precursors used to make it, alongside the wider availability of the overdose-reversal drug naloxone and a drop in demand as fewer young people start using. DEA data show the purity of street fentanyl fell after 2022 [1]. Those are the factors the people who track the drug credit for the turn, and none of them is a border operation.
The enforcement story also runs into a stubborn fact: the seizures went down, not up. Customs and Border Protection's fentanyl seizures at the US-Mexico border fell to about 11,486 pounds in 2025, the fewest since 2021, a drop of roughly 57 percent from 2023 [2]. A crackdown that was catching more fentanyl at the border would show rising seizures. Falling seizures are consistent with less fentanyl being produced and moved, which is the supply-side explanation, not the enforcement one.
The distinction is not academic. If the decline is coming from a weaker supply and from naloxone and treatment reaching more people, then the way to keep it going is to protect those things. Crediting a crackdown instead points the next budget toward enforcement and away from the measures the research actually links to the drop. The lives behind a 13 percent decline are worth getting the cause right, because the cause is what tells you how to keep it falling.
